Price
Target price
€9.50
€9.50
-1.040%
-0.1
-1.040%
€10.62
21.11.25 / Stuttgart Stock Exchange
WKN: 897013 / Symbol: IART / Name: Integra / Stock / Healthcare Equipment & Supplies / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Integra LifeSciences Holdings Corp Stock
A loss of -1.040% shows a downward development for Integra LifeSciences Holdings Corp.
Our community is currently low on Integra LifeSciences Holdings Corp with 1 Buy predictions and 5 Sell predictions.
However, we have a potential of 5.26% for Integra LifeSciences Holdings Corp as the target price of 10 € is above the current price of 9.5 €.
Pros and Cons of Integra LifeSciences Holdings Corp in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
B****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Integra LifeSciences Holdings Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Integra LifeSciences Holdings Corp | -1.040% | -5.941% | -27.481% | -57.965% | -55.189% | -81.731% | -79.258% |
| Icu Medical Inc. | 0.870% | -0.855% | 14.851% | -27.950% | -21.088% | -23.684% | -25.161% |
| Bio-Rad Labs Inc. A | 4.890% | 2.041% | -4.514% | -13.982% | -12.448% | -29.197% | -41.489% |
| Neogen Corp. | -2.130% | -10.270% | -2.353% | -64.429% | -58.500% | - | - |
Comments
Integra LifeSciences (NASDAQ:IART) had its price target lowered by analysts at Citigroup Inc. from $12.00 to $11.00. They now have a "sell" rating on the stock.
Show more
Ratings data for IART provided by MarketBeat
Integra LifeSciences (NASDAQ:IART) had its price target raised by analysts at JPMorgan Chase & Co. from $12.00 to $13.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for IART provided by MarketBeat
Integra LifeSciences (NASDAQ:IART) had its "sell" rating reaffirmed by analysts at Citigroup Inc..
Show more
Ratings data for IART provided by MarketBeat
News
Integra (IART) Q2 Revenue Beats by 5%
Integra LifeSciences (NASDAQ:IART), a medical technology company specializing in neurosurgery, reconstructive, and tissue technologies, released its results for Q2 2025 on July 31, 2025. The most
